
|Articles|February 25, 2022
HER2 Biomarker Testing in Breast and Gastrointestinal Cancers: The Role of the Pathologist
This publication provides a summary of key stakeholder insights on methodological limitations and analytical factors to consider pertaining to biomarker testing for HER2+ across cancer types, with particular emphasis on the role of the pathologist in the multidisciplinary management of cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5




































